JPMorgan Chase & Co. Has $48.89 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

JPMorgan Chase & Co. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 16.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,166 shares of the company's stock after selling 28,073 shares during the period. JPMorgan Chase & Co. owned about 0.47% of Medpace worth $48,893,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after acquiring an additional 25,704 shares in the last quarter. State Street Corp grew its position in shares of Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after purchasing an additional 50,312 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock valued at $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after purchasing an additional 109,886 shares during the last quarter. Finally, GW&K Investment Management LLC grew its position in Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after buying an additional 133,379 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of recent research reports. Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Truist Financial decreased their price objective on Medpace from $347.00 to $333.00 and set a "hold" rating on the stock in a report on Thursday. Leerink Partners initiated coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Mizuho decreased their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $361.90.

Medpace Stock Down 5.0 %

MEDP stock traded down $15.00 during trading on Thursday, hitting $287.56. The company had a trading volume of 121,811 shares, compared to its average volume of 366,630. The firm has a 50-day moving average price of $325.79 and a 200-day moving average price of $335.08. Medpace Holdings, Inc. has a 12 month low of $271.99 and a 12 month high of $459.77. The stock has a market cap of $8.69 billion, a price-to-earnings ratio of 22.77, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.